EC Number |
Inhibitors |
Structure |
---|
1.14.19.20 | (3S,20S)-20-N-(2-methylpropyl)carbamoylpregn-7-en-3beta-ol |
specific |
|
1.14.19.20 | (3S,20S)-20-N-(2-methylpropyl)carbamoylpregn-7-en-3beta-yl acetate |
specific for the enzyme. Prodrug, transformed into the 3beta-hydroxy derivative under in vitro conditions |
|
1.14.19.20 | (3S,20S)-20-N-butylcarbamoylpregn-7-en-3beta-ol |
specific |
|
1.14.19.20 | (3S,20S)-20-N-butylcarbamoylpregn-7-en-3beta-yl acetate |
specific for the enzyme. Prodrug, transformed into the 3beta-hydroxy derivative under in vitro conditions |
|
1.14.19.20 | (3S,20S)-20-N-ethylcarbamoylpregn-7-en-3beta-ol |
- |
|
1.14.19.20 | (3S,20S)-20-N-ethylcarbamoylpregn-7-en-3beta-yl acetate |
- |
|
1.14.19.20 | (3S,20S)-20-N-pentylcarbamoylpregn-7-en-3beta-ol |
specific |
|
1.14.19.20 | (3S,20S)-20-N-pentylcarbamoylpregn-7-en-3beta-yl acetate |
specific for the enzyme. Prodrug, transformed into the 3beta-hydroxy derivative under in vitro conditions |
|
1.14.19.20 | (3S,20S)-20-N-propylcarbamoylpregn-7-en-3beta-ol |
- |
|
1.14.19.20 | (3S,20S)-20-N-propylcarbamoylpregn-7-en-3beta-yl acetate |
- |
|